
|Videos|January 30, 2023
The Role of Ruxolitinib in Myelofibrosis Treatment
Author(s)Joshua Richter, MD, Srdan Verstovsek, MD, PhD
Dr Srdan Verstovsek discusses how ruxolitinib might fit into the myelofibrosis treatment landscape in the future, and highlights remaining unmet needs.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5









































